Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Regulation

Feb. 1 Quick Takes: FDA approves GSK’s daprodustat

Plus: Patient Square caps first fund at $3.9B, and updates from Verily-Otsuka Novartis, Evelo, Sherlock-Sense, Recurv and more

February 2, 2023 1:09 AM UTC

Jesduvroq daprodustat from GSK plc (LSE:GSK; NYSE:GSK) became the U.S.’s first oral treatment for anemia caused by chronic kidney disease (CKD), following its FDA approval on Wednesday in the indication. The agency restricted Jesduvroq’s approval to patients who have been receiving dialysis for at least four months, consistent with the recommendation of the agency’s Cardiovascular and Renal Drugs Advisory Committee, which voted on the HIF stabilizer last October.

Three-year-old private equity firm Patient Square Capital said it has closed its inaugural fund with $3.9 billion, well above its $3 billion target. The firm has already deployed $3 billion across the healthcare spectrum, with deals including its lead roles in a $145 million round for U.K.-based Apollo Therapeutics and a $270 million series C round for gene therapy play Kriya Therapeutics Inc., as well as its agreement with Gurnet Point Capital to take Radius Health Inc. private. The firm also launched Enavate Sciences last year to invest in mid-stage rounds. Jim Momtazee, who headed healthcare investments at KKR, is Patient Square’s managing partner...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article